文献速递前列腺癌

多学科团队会议在日常实践中实施转移性前列腺癌化疗联合激素治疗的作用

Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-07-07

基于荷兰癌症登记处2015年10月至2016年4月诊断的962例转移性前列腺癌患者,分析多学科团队会议(MDT)对接受化疗联合激素治疗的影响。MDT讨论与接受化疗联合激素治疗独立相关(OR 2.77,95%CI 1.68-4.59),化疗联合激素治疗组2年总生存率为82.1%(95%CI 78.5-85.6%),单用雄激素剥夺治疗组为59.9%(95%CI 55.4-64.4%)。

要点

  • MDT讨论与转移性前列腺癌患者接受化疗联合激素治疗独立相关(OR 2.77,95%CI 1.68-4.59)。
  • 化疗联合激素治疗组2年总生存率82.1%(95%CI 78.5-85.6%),单用ADT组59.9%(95%CI 55.4-64.4%)。
  • 年轻、合并症少、体能状态好和高瘤负荷疾病与接受化疗联合激素治疗显著相关。

核心结论

  • 被MDT讨论与转移性前列腺癌患者接受化疗联合激素治疗独立相关,支持MDT组织结构促进创新治疗方案实施的假设。

研究设计与样本

  • 基于人群的荷兰癌症登记处研究,纳入2015年10月至2016年4月诊断的所有转移性前列腺癌患者(n=962)。
  • 采用逻辑回归分析患者和肿瘤特征(特别关注MDT)与接受化疗联合激素治疗 vs 单用ADT的关系,用Kaplan-Meier曲线评估总生存。

主要发现

  • 接受ADT单药治疗与化疗联合激素治疗的患者数量相等(各n=452)。
  • 被MDT讨论、较年轻、合并症较少、体能状态较好和高瘤负荷疾病与接受化疗联合激素治疗而非ADT单药治疗显著相关。
  • 调整这些因素后,MDT的存在与接受化疗联合激素治疗独立相关(OR 2.77,95%CI 1.68-4.59)。
  • 化疗联合激素治疗组2年总生存率为82.1%(95%CI 78.5-85.6%),ADT单药治疗组为59.9%(95%CI 55.4-64.4%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The recommended treatment for a subset of patients with metastatic prostate cancer (mPC) changed from androgen deprivation therapy (ADT) to combinations with chemotherapy such as docetaxel. Implementation of new evidence from trials is however complex and challenging. We investigated the effect of multidisciplinary team meetings (MDTs) on adopting the newest emerging combination therapy in patients with mPC and assessed the overall survival of chemohormonal therapy in a real-world setting. METHODS: All mPC patients diagnosed between October 2015 and April 2016 in the Netherlands were identified from the population-based Netherlands Cancer Registry (n = 962). Logistic regression analyses were performed to examine the role of patient- and tumor characteristics, with special emphasis on MDTs, on receiving chemohormonal therapy versus ADT monotherapy. Kaplan-Meier survival curves were used to assess overall survival (OS). RESULTS: As many patients received ADT monotherapy as chemohormonal therapy (both n = 452). Being discussed in a MDT as patient, younger age, less comorbidities, a better performance status and high-volume disease were significantly associated with receiving chemohormonal therapy compared to ADT monotherapy. After adjustment for these factors, the presence of a MDT was independently associated with the administration of chemohormonal therapy (OR 2.77, 95% CI 1.68-4.59). The 2-year OS was 82.1% (95% CI: 78.5-85.6%) for patients receiving chemohormonal therapy and 59.9% (95% CI: 55.4-64.4%) for patients receiving ADT monotherapy. CONCLUSION: Being discussed in a MDT is independently associated with the administration of chemohormonal therapy in this group of patients with mPC. This supports the hypothesis that implementation of innovative treatment options is facilitated by an organizational structure with MDTs.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Creemers SG, Van Santvoort B, van den Berkmortel FWPJ, et al. Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice. Prostate Cancer Prostatic Dis. 2022. PMID: 35798856. doi:10.1038/s41391-022-00556-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。